1. Home
  2. PRSU vs CAPR Comparison

PRSU vs CAPR Comparison

Compare PRSU & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRSU

Pursuit Attractions and Hospitality Inc.

HOLD

Current Price

$47.33

Market Cap

1.4B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$4.32

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSU
CAPR
Founded
1926
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
1994
2011

Fundamental Metrics

Financial Performance
Metric
PRSU
CAPR
Price
$47.33
$4.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$31.67
$44.63
AVG Volume (30 Days)
206.8K
5.7M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,064,987,000.00
N/A
Revenue This Year
$4.85
N/A
Revenue Next Year
$4.94
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
9.48
N/A
52 Week Low
$32.03
$2.96
52 Week High
$56.52
$40.37

Technical Indicators

Market Signals
Indicator
PRSU
CAPR
Relative Strength Index (RSI) 38.11 16.61
Support Level $32.90 $4.23
Resistance Level $54.24 $6.54
Average True Range (ATR) 1.87 0.80
MACD -0.63 0.07
Stochastic Oscillator 25.62 7.90

Price Performance

Historical Comparison
PRSU
CAPR

About PRSU Pursuit Attractions and Hospitality Inc.

Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, Iceland and Costa Rica. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: